stockportfolio.pro
Stocks / ANAB vs PGEN
ANAB vs PGEN
AnaptysBio, Inc. and Precigen, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| AnaptysBio, Inc. (ANAB) | Precigen, Inc. (PGEN) | |
|---|---|---|
| Market cap | $1.6B | $1.6B |
| Revenue (latest FY) | $234.60M | $9.68M |
| Net income (latest FY) | $-13.23M | $-250.64M |
| Revenue growth (5y CAGR) | 25.6% | -21.3% |
| Net margin | -5.6% | -2588.2% |
| Return on equity | -35.6% | -1198.6% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 1 |
| Positive free cash flow | Yes | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open ANAB — free Open PGEN — freeFrequently asked questions
Which is bigger, ANAB or PGEN?
Precigen, Inc. is larger by market capitalization — $1.6B versus $1.6B.
Which grows faster, ANAB or PGEN?
Over the last five fiscal years, AnaptysBio, Inc. grew revenue faster — 25.6%/yr versus -21.3%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.